Lyra Therapeutics, Inc. LYRA
0.20
0.17
566.67%
as of 25 Sep
- Market cap
- $870.0K
- P/E
- 0.0×
Follow LYRA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — |
P/S ratio |
12.02 | 8.76 | 166.23 | 68.54 | 0.00 | — | — | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — |
P/Operating CF |
(0.79) | (1.18) | (13.59) | (7.68) | (5.01) | — | — | (1.06) | — |
P/B ratio |
0.00 | 1.16 | 2.90 | 1.16 | 1.65 | — | — | 0.00 | — |
Price to Tangible BV |
0.00 | 1.16 | 2.90 | 1.16 | 1.65 | — | — | 0.00 | — |
EV/Sales |
(27.91) | (17.69) | 100.28 | (3.28) | 0.00 | — | — | 0.00 | — |
EV/EBITDA |
0.36 | 0.28 | 0.00 | 0.08 | 0.00 | — | — | 1.81 | — |
EV/Operating CF |
0.39 | 0.39 | (2.47) | 0.10 | (0.42) | — | — | 2.10 | — |
EV/FCF |
0.38 | 0.38 | (2.43) | 0.10 | (0.37) | — | — | 2.07 | — |
Quick Ratio |
1.67 | 3.21 | 5.24 | 6.77 | 2.51 | 15.27 | 1.88 | 12.27 | — |
Current Ratio |
1.71 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 | 1.94 | 12.72 | — |
Net Debt/EBITDA |
0.52 | 0.41 | 1.46 | 1.76 | 1.07 | 3.37 | 0.59 | 3.33 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.10 | — |
Operating CF/Net income |
1.00 | 0.75 | 1.01 | 0.78 | 0.59 | 0.96 | 0.84 | 1.09 | — |
Capex/Depreciation |
(0.21) | 1.30 | 0.33 | (0.29) | (3.38) | (18.68) | (7.81) | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (6,594.98%) | (184.99%) | (73.67%) | (96.08%) | (79.98%) | 90.60% | 14.15% | 5.30% | — | |
| (56.45%) | (89.43%) | (49.63%) | (67.07%) | (64.13%) | (46.20%) | (80.88%) | (48.19%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(370.71%) | (293.84%) | (71.83%) | (62.39%) | (127.32%) | (30.23%) | (316.74%) | (26.48%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 49.00 | — |
Research and Development Expense of Revenue |
4,625.88% | 2,853.06% | 3,082.73% | 2,846.44% | 10,418.95% | 0.00% | 0.00% | 399.92% | — |
Selling, General and Administrative Expense of Revenue |
2,899.50% | 1,206.06% | 1,223.17% | 1,288.04% | 4,984.56% | 0.00% | 0.00% | 277.01% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
586.68% | 437.81% | 377.86% | 399.63% | 971.93% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
(6.39) | (0.87) | 0.20 | 0.77 | 0.48 | — | — | 6.60 | — |
Graham Number |
54.53 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — |
Earnings Yield |
(621.75%) | (692.83%) | (24.81%) | (68.14%) | (76.83%) | — | — | (421.93%) | — |
Free Cash Flow Yield |
(604.17%) | (538.45%) | (24.85%) | (46.61%) | (51.59%) | — | — | (349.82%) | — |
Revenue per Share |
0.26 | 1.18 | 1.56 | 2.25 | 1.10 | 0.00 | 0.00 | 0.10 | — |
Operating CF per Share |
(18.58) | (53.77) | (63.55) | (71.75) | (99.42) | (123.07) | (3,438.50) | (0.51) | — |
Capex per Share |
(0.06) | (1.80) | (1.05) | (0.27) | (13.03) | (10.33) | (52.75) | 0.00 | — |
Free Cash Flow per Share |
(18.65) | (55.57) | (64.60) | (72.02) | (112.46) | (133.40) | (3,491.25) | (0.51) | — |
Cash per Share |
10.23 | 31.17 | 103.16 | 161.89 | 176.15 | 434.19 | 2,452.00 | 1.85 | — |
Shareholders Equity per Share |
(6.90) | 8.90 | 89.77 | 133.54 | 132.14 | 433.60 | 1,832.00 | 1.80 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(6.90) | 8.90 | 89.77 | 133.54 | 132.14 | 433.60 | 1,832.00 | 1.80 | — |
Free Cash Flow |
(28.96) | (72.35) | (64.35) | (43.55) | (29.20) | (22.92) | (13.96) | (6.64) | — |
Working Capital |
6.75 | 30.39 | 85.22 | 86.36 | 29.67 | 71.03 | 4.91 | 22.97 | — |
Capital Expenditures |
(0.10) | (2.34) | (1.05) | (0.16) | (3.38) | (1.77) | (0.21) | (0.04) | — |
Net Current Asset Value |
(30.55) | (11.73) | 51.64 | 71.62 | 27.37 | 69.58 | 2.48 | 22.85 | — |
EV/EBIT |
0.36 | 0.28 | 0.00 | 0.08 | 0.00 | — | — | 1.81 | — |
Capex to Sales |
0.25 | 1.52 | 0.67 | 0.12 | 11.88 | 0.00 | 0.00 | 0.00 | — |
Net Profit Margin |
(7,266.08%) | (6,090.94%) | (4,023.11%) | (4,055.61%) | (15,267.72%) | 0.00% | 0.00% | (491.16%) | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.44 | (1.29) | (1.58) | 0.26 | 0.22 | 0.04 | 0.11 | 0.80 | — |
Cash ROIC |
(577.86%) | (136.89%) | (34.00%) | (25.54%) | (37.87%) | (15.63%) | (81.65%) | (14.30%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Payables |
0.92 | 2.16 | 2.87 | 2.87 | 2.02 | 1.00 | 0.85 | 0.85 | — |
Average Assets |
51.23 | 104.47 | 126.28 | 82.42 | 67.85 | 47.90 | 20.16 | 12.68 | — |
Average Common Equity |
0.44 | 50.51 | 85.09 | 57.54 | 54.40 | (24.42) | (115.21) | (115.21) | — |
Columns are period end dates